Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions 06 November
